#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17336	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2836	743.6	0	.	n	.	0	A69G	SNP	69	69	A	642	642	G	1048	G,A,T	769,275,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17336	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2836	743.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	2023	2023	T	1158	T,C,A,G	1148,6,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17336	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2836	743.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1757	1757	C	1066	C,A	1065,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17336	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2836	743.6	0	HET	.	.	.	T454TG	.	454	454	T	1027	1027	T	1096	TG,T	794,282	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29782	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4129	900.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	2037	2037	A	1200	A,T	1198,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29782	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4129	900.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2671	2671	C	1090	C,T,G	1085,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29782	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4129	900.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2745	2745	A	1011	A,C	1010,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29782	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4129	900.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3297	3297	C	1060	C,T	1059,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2476	folP	852	852	99.88	folP.l6.c17.ctg.1	2024	152.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	988	990	AAA	246;248;251	A;A,C;A	246;247,1;251	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2476	folP	852	852	99.88	folP.l6.c17.ctg.1	2024	152.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1219	1221	AGC	243;242;243	A;G;C,G	243;242;242,1	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5880	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3890	188.6	1	SNP	p	S91F	0	.	.	271	273	TCC	886	888	TCC	221;221;220	T;C;C	221;221;220	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5880	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3890	188.6	1	SNP	p	D95N	0	.	.	283	285	GAC	898	900	GAC	224;224;221	G;A;C	224;224;221	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5880	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3890	188.6	1	SNP	p	D95G	0	.	.	283	285	GAC	898	900	GAC	224;224;221	G;A;C	224;224;221	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	2248	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1956	143.6	1	SNP	p	G45D	0	.	.	133	135	GGC	805	807	GGC	231;233;229	G;G,A;C	231;231,2;229	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1242	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1600	96.9	0	.	n	.	0	A197.	DEL	197	197	A	831	831	A	266	A,C	264,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5568	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3484	199.5	1	SNP	p	D86N	0	.	.	256	258	GAC	905	907	GAC	245;245;244	G;A,C;C	245;244,1;244	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5568	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3484	199.5	1	SNP	p	S87R	0	.	.	259	261	AGT	908	910	AGT	245;241;241	A;G;T	245;241;241	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5568	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3484	199.5	1	SNP	p	S87W	0	.	.	259	261	AGT	908	910	AGT	245;241;241	A;G;T	245;241;241	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5568	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3484	199.5	1	SNP	p	S87I	0	.	.	259	261	AGT	908	910	AGT	245;241;241	A;G;T	245;241;241	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5568	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3484	199.5	1	SNP	p	S88P	0	.	.	262	264	TCC	911	913	TCC	242;243;249	T,G;C,G;C	241,1;242,1;249	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4940	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3236	190.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1905	1907	GGC	274;276;277	G;G;C,G	274;276;276,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1530	1532	GCA	268;268;267	G;C,A;A	267;266,1;266	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1533	1535	ATC	268;266;266	A;T;C	267;265;265	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1545	1547	GTG	266;264;264	G;T;G	265;263;263	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1545	1547	GTG	266;264;264	G;T;G	265;263;263	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2049	2051	ACC	239;239;241	A,T;C;C,A	238,1;239;240,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2103	2105	GCG	248;251;247	G;C,G;G	248;250,1;247	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2103	2105	GCG	248;251;247	G;C,G;G	248;250,1;247	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2226	2228	GGC	240;241;246	G,C,A;G;C	238,1,1;241;246	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2235	2237	GGC	249;247;248	G;G;C	249;247;248	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4524	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2990	188.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2253	2255	CTG	250;252;254	C;T,C,G;G,A	250;248,3,1;253,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6310	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3678	214.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1935	1937	CCG	256;255;255	C,G;C;G,A	255,1;255;254,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2870	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2318	154.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	876	876	C	212	C	212	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	26;29;31	T;T;A	26;29;31	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	61;61;61	C;A;T	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	61;61;61	A;G;T	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	61;61;61	T;A;C	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;4	G;C;C	3;3;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	348	28.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	181	62.1	0	.	p	.	0	M18T	NONSYN	52	54	ATG	132	134	ACG	77;74;70	A;C;G	77;74;70	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	326	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	181	62.1	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	174	176	CAA	21;20;19	C;A;A	21;20;19	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	585	587	GAA	321;320;320	G;A;A,T	321;320;319,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	873	875	GAT	324;326;321	G,A;A;T,G	323,1;326;320,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	996	998	TCA	302;308;309	T;C;A,G,C	302;308;307,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1125	1127	GTC	274;273;270	G;T;C	274;273;270	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1137	1139	TCT	266;267;270	T;C;T	266;267;270	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1455	1457	GCA	287;291;291	G;C;A	287;291;291	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	1	SNP	p	G120K	1	.	.	358	360	AAG	831	833	AAG	305;305;308	A,C;A;G	304,1;305;308	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	1	SNP	p	D121N	0	.	.	361	363	GAC	834	836	GAC	308;309;314	G;A;C	308;309;314	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3538	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1965	223.8	1	SNP	p	A121D	1	.	.	361	363	GAC	834	836	GAC	308;309;314	G;A;C	308;309;314	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	12034	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5304	283.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2219	2221	AAT	331;329;330	A,C;A,G;T	330,1;328,1;330	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1776	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1562	142.0	1	SNP	p	V57M	1	.	.	169	171	ATG	766	768	ATG	327;331;330	A;T;G	327;331;330	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
